Navigation Links
Formedix to Host Executive Breakfast prior to Bay Area CDISC Network Meeting, May 23, 2013
Date:5/8/2013

Burlington, MA (PRWEB) May 08, 2013

Formedix, a leading provider of CDISC based clinical trial automation software and consultancy services, is hosting an executive breakfast on May 23, 2013 from 9 am, prior to the Bay Area CDISC Network Meeting, this year sponsored by Formedix. The event is being held in the South San Francisco Conference Center.

Mark Wheeldon, of Formedix, will be joined at the morning event by CEO of CDISC Rebecca Kush and David Borbas, Senior Director of Data Management at Jazz Pharmaceuticals for presentations celebrating CDISC standards and their use within the clinical trial process. The breakfast will provide attendees with the opportunity to hear industry specialists’ opinions on CDISC standards and their application throughout a clinical trial, as well as the chance to enjoy high-level networking.

The executive breakfast will lead up to the Bay Area CDISC Network Meeting, to be held at 1 pm in the same location, where Mark Wheeldon, CEO of Formedix, this year’s event sponsor, will also be presenting all about Define-XML and the business benefits of using this standard in your clinical trials.

Mark Wheeldon says, “Formedix is delighted to be sponsoring this year’s Bay Area CDISC Network Meeting, as well as to be back presenting at the event. We also relish the opportunity to be able to host our own executive breakfast meeting prior to the event to hear from other industry specialists and meet with life science industry members to discuss CDISC standards and how others are currently working with them.”

He also adds, “CDISC Standards are vendor-neutral and portable; they can be reused across a whole trial across multiple platforms so we are always interested to find out where people are using them and offer our help and advice.”

For more information and to register for the free networking event, visit the event page. The invitation is open to any interested industry professionals at any point in their CDISC adoption cycle, as well as those in the area to attend the Bay Area CDISC User Group in the afternoon.

About Formedix

Formedix clinical trial automation software and services enable you to remove manual, expensive, inefficient and labor intensive tasks from study set-up, EDC build, validation and submission publication processes.

In fact, across every area of your end-to-end clinical trial, the time and cost savings they deliver speak for themselves and continue to do so time and time again.

Formedix saves 68% in set-up time and 55% in EDC build time. With 70% reuse of your content, resources are cut by 23%. It’s all in the numbers.

Your Clinical Trials Automated. Everywhere.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10713648.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. "Collaborate to Innovate" with Formedix at DIA Annual Meeting 2012
2. Formedix Partners with Perceptive Informatics for Forthcoming Webcast, “Four Secrets to Using CDISC Standards to Enable Clinical Trial Efficiencies”
3. Formedix to Host Webinar: Discover Define-XML - Practical Uses Today and a Technical Deep Dive on March 14, 2013
4. Formedix and OmniComm Partner to Offer CRO and Sponsors Multi-Vendor EDC Capabilities
5. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
6. Biocartis Names Dr. Nayan Gregory Parekh As Chief Executive Officer
7. GenVec President and Chief Executive Officer Announces Retirement
8. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
9. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
10. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
11. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016 Eutilex Co. Ltd. today announced ... $18.9M) Series A financing. This financing round included participation ... and SNU Bio Angel. This new funding brings the ... (US $27.7M) since its founding in 2015. ... development and commercialization of its immuno-oncology programs, expand its ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... phase I/II dose escalation and expansion clinical trial for its lead drug candidate, ... The purpose of the trial was to determine the safety, antitumor activity, and ...
(Date:12/7/2016)... Dec. 7, 2016 Neogen Corporation (NASDAQ: ... Dan Kephart as its chief science officer ... assume his responsibilities at Neogen effective Jan. 1. ... for the agribusiness unit of Thermo Fisher Scientific, as ... Life Technologies. His extensive industry experience also includes the ...
(Date:12/7/2016)... OTTAWA, Ontario , Dec. 7, 2016 /PRNewswire/ ... partnership with General Atomics (GA), welcome today,s award ... National Nuclear Security Administration (NNSA) of the Phase ... its project with Nordion and the University of ... Phase II funding will support the establishment of ...
Breaking Biology Technology:
(Date:6/21/2016)... Columbia , June 21, 2016 ... to the new role of principal product architect ... named the director of customer development. Both will ... chief technical officer. The moves reflect NuData,s strategic ... in response to high customer demand and customer ...
(Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
(Date:6/9/2016)... control systems is proud to announce the introduction of fingerprint attendance control software, allowing ... are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
Breaking Biology News(10 mins):